Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

著者: Elizabeth J. Phillips, Chonlaphat Sukasem, Michelle Whirl‐Carrillo, Daniel J. Müller, Henry M. Dunnenberger, Wasun Chantratita, Barry R. Goldspiel, Yuan‐Tsong Chen, Bruce Carleton, Alfred L. George, Taisei Mushiroda, Teri E. Klein, Roseann S. Gammal, Munir Pirmohamed - Clinical Pharmacology & Therapeutics 2018 被引用: 302

The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.